When was GrannuS founded?

GrannuS was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is GrannuS located?

GrannuS is headquartered in Indianapolis, United States.

Who is the current CEO of GrannuS?

John Foglesong of GrannuS. They have also founded 1 company.

Is GrannuS a funded company?

GrannuS is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Aug 01, 2020.

When was the latest funding round of GrannuS?

GrannuS's latest funding was a $***** Conventional Debt round on Nov 17, 2023, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $1.03B in funding in 2026 to date.

Where does GrannuS rank among its competitors?

GrannuS ranks 1794th amongst 3167 active competitors, of which 1085 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was C4 Therapeutics, which secured $25M in Jan, 2024.

Who are the top competitors of GrannuS?

GrannuS's top competitors include Jazz Pharmaceuticals, Kite Pharma and Advanced Accelerator Applications. Among them, C4 Therapeutics secured the most recent funding round in January, 2024.

GrannuS - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of small molecule inhibitors for the treatment of oncology. The company is focused on developing small molecule inhibitors of HSP90𝛽 for the treatment of multiple types of cancer delivering the benefits of previous pan-inhibitors without the toxicity and dosing challenges.

Key Metrics

Founded Year

2019

Location

Indianapolis, United States

Stage

Funding Raised

Latest Funding Round

Conventional Debt, Nov 17, 2023, $*****

Investors

Plug and Play Tech Center & 1 more

Ranked

1794^th among 3167 active competitors

Similar Companies

Jazz Pharmaceuticals & 2946 more

View GrannuS's full profile

GrannuS has raised funding over 3 rounds. Its first funding round was on Aug 01, 2020. GrannuS has 2 institutional investors.

Here is the list of recent funding rounds of GrannuS:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 17, 2023	7813298	Conventional Debt	3236895	8945829	7850329	1149747
Sep 01, 2021	9483245	Grant (prize money)	4063591	9066477	6354601	HHS
Aug 01, 2020	5390495	Grant (prize money)	7370749	3645016	7591682	HHS

Access funding benchmarks and valuations. Sign up today!

View details of GrannuS's funding rounds and investors

The founders of GrannuS are John Foglesong, Brian Blagg and Sanket Mishra. John Foglesong is the CEO of GrannuS.

Here are the details of GrannuS's key team members:

John Foglesong: Co-Founder & CEO of GrannuS.
Contact Info: 1 email address
Brian Blagg: Co-Founder of GrannuS.
Contact Info: 1 email address
Sanket Mishra: Co-Founder of GrannuS.
Contact Info: 1 email address

View details of GrannuS's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of GrannuS include Jazz Pharmaceuticals, Kite Pharma and Advanced Accelerator Applications. Here is the list of Top 10 competitors of GrannuS, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Vivo Capital & 10 others	79/100
3rd	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Vivo Capital, Tamburi Investment Partners ... & 4 others	78/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, Baillie Gifford & 17 others	75/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
6th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
7th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of drugs based on T-Cell receptor technology for the treatment of cancer	$601M	BlackRock, General Atlantic & 50 others	74/100
8th	FibroGen 1993, San Francisco (United States), Public	Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology.	$215M	Adage Capital Management, Corriente Biotechnology Partners ... & 26 others	72/100
9th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
10th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
1794th	GrannuS 2019, Indianapolis (United States), Funding Raised	Developer of small molecule inhibitors for the treatment of oncology	-	Plug and Play Tech Center, HHS	29/100